2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[d][1,2,3]triazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[d][1,2,3]triazole
• 英文别名: 2-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzotriazole；2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzotriazole
• 化学式: C₁₃H₁₈BN₃O₂
• 分子量: 259.116
• InChiKey: AOVPXTQRVIHAOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.27
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  49.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[d][1,2,3]triazole 在 sodium periodate 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 以46 %的产率得到2-methyl-2H-1,2,3-benzotriazole-5-boronic acid
  参考文献：
  名称：

  [EN] KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
  [FR] INHIBITEURS DE KDM1A POUR LE TRAITEMENT D'UNE MALADIE

  摘要：

  Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

  公开号：

  WO2023069884A1
• 作为产物：
  描述：

  5-溴-1H-苯并噻唑 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 sodium hydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 mineral oil 为溶剂， 反应 0.08h， 生成 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[d][1,2,3]triazole
  参考文献：
  名称：

  [EN] KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
  [FR] INHIBITEURS DE KDM1A POUR LE TRAITEMENT D'UNE MALADIE

  摘要：

  Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

  公开号：

  WO2023069884A1

文献信息

• [EN] 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES DE TYPE 3-(1H-PYRAZOL-4-YL)PYRIDINE DU RÉCEPTEUR MUSCARINIQUE M4 D'ACÉTYLCHOLINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2019005587A1

  公开（公告）日：2019-01-03

  The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及吡唑-4-基吡啶化合物，这些化合物是M4肌制酸乙酰胆碱受体的变构调节剂。本发明还涉及所述化合物在潜在治疗或预防M4肌制酸乙酰胆碱受体参与的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗M4肌制酸乙酰胆碱受体参与的疾病中的用途。
• Controlling the Emissive, Chiroptical, and Electrochemical Properties of Double [7] Helicenes through Embedded Aromatic Rings
  作者：Juan Hong、Xuxian Xiao、Haoliang Liu、Evgenia Dmitrieva、Alexey A. Popov、Zidong Yu、Ming‐De Li、Tatsuhiko Ohto、Jun Liu、Akimitsu Narita、Pengcai Liu、Hirokazu Tada、Xiao‐Yu Cao、Xiao‐Ye Wang、Yingping Zou、Klaus Müllen、Yunbin Hu

  DOI：10.1002/chem.202202243

  日期：2022.10.18

  Controlling the photophysics of double helicenes is facilely achieved by variation of the terminal aromatic rings. Compared to the thiadiazole-fused and all-carbon analogs, triazole-fused double helicene shows significantly enhanced emission with near-unity quantum yield, and high circularly polarized luminescence brightness of up to 30.1 M−1 cm−1, as well as excellent ambipolar redox behavior.

  通过改变末端芳环可以轻松控制双螺旋的光物理。与噻二唑稠合和全碳类似物相比，三唑稠合双螺旋体显示出显着增强的发射，具有接近统一的量子产率，高达 30.1 M -1  cm -1的高圆偏振发光亮度，以及优异的双极性氧化还原行为。
• 有机化合物及其应用、紫外光转换封装胶膜及其制备方法、光伏组件
  申请人：江苏绿人半导体有限公司

  公开号：CN118026943A

  公开（公告）日：2024-05-14

  本发明涉及太阳能电池领域，公开了有机化合物及其应用、紫外光转换封装胶膜及其制备方法、光伏组件，该有机化合物具有式(I)所示的结构。本发明的有机化合物添加到胶膜中，作为紫外光转换封装胶膜，应用于太阳能电池组件，可见光透光率高，可对紫外线的吸收有良好吸收，且将紫外线转化为可见光，进而对太阳能光伏组件的转化效率及耐候性有显著提高。#imgabs0#
• CN114591340
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE KDM1A POUR LE TRAITEMENT D'UNE MALADIE
  申请人：[en]IMAGO BIOSCIENCES, INC.

  公开号：WO2023069884A1

  公开（公告）日：2023-04-27

  Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.